1.Supraclavicular lymph node tuberculosis presenting with immune thrombocytopenic purpura.
Hua LU ; Yong-ren WANG ; Ou JI ; Wei XU ; Jian-fu ZHANG ; Qin-he FAN ; Jian-yong LI
Chinese Medical Journal 2007;120(19):1730-1731
2.Recent Advances in SARS-CoV-2-Induced Immune Thrombocytopenia --Review.
Xin-Hui ZHOU ; Chang-Geng RUAN ; Yang HE
Journal of Experimental Hematology 2023;31(2):593-597
SARS-CoV-2-induced immune thrombocytopenia (SARS-CoV-2-induced ITP) is an autoimmune disease secondary to virus infections. Its diagnosis is often based on exclusion of other possible causes of thrombocytopenia in COVID-19 patients. Common laboratory examinations include coagulation function, thrombopoietin and drug-dependent antibodies. Since both bleeding and thrombosis risks are seen in SARS-CoV-2-induced ITP patients, individual remedy is essential for the treatment of this disease. Because thrombopoietin receptor agonist(TPO-RA) has the side effect of accelerating thrombosis and may aggravate the pulmonary embolism symptoms of patients, it should be used for refractory SARS-CoV-2-induced ITP patients only. This review briefly summarizes the recent research progress in the pathogenesis, diagnosis and treatment of SARS-CoV-2-induced ITP.
Humans
;
Purpura, Thrombocytopenic, Idiopathic/drug therapy*
;
SARS-CoV-2
;
COVID-19/complications*
;
Thrombocytopenia
;
Thrombosis/drug therapy*
;
Thrombopoietin/therapeutic use*
;
Recombinant Fusion Proteins/therapeutic use*
4.Hyperglycemic Hyperosmolar Syndrome Caused by Steroid Therapy in a Patient with Lupus Nephritis.
Seok Hui KANG ; Ja Young LEE ; Hoon Suk PARK ; In O SUN ; Sun Ryoung CHOI ; Byung Ha CHUNG ; Bum Soon CHOI ; Chul Woo YANG ; Yong Soo KIM ; Cheol Whee PARK
Journal of Korean Medical Science 2011;26(3):447-449
A 51-yr-old female was referred to our outpatient clinic for the evaluation of generalized edema. She had been diagnosed with idiopathic thrombocytopenic purpura (ITP). She had taken no medicine. Except for the ITP, she had no history of systemic disease. She was diagnosed with systemic lupus erythematosus. Immunosuppressions consisting of high-dose steroid were started. When preparing the patient for discharge, a generalized myoclonic seizure occurred at the 47th day of admission. At that time, the laboratory and neurology studies showed hyperglycemic hyperosmolar syndrome. Brain MRI and EEG showed brain atrophy without other lesion. The seizure stopped after the blood sugar and serum osmolarity declined below the upper normal limit. The patient became asymptomatic and she was discharged 10 weeks after admission under maintenance therapy with prednisolone, insulin glargine and nateglinide. The patient remained asymptomatic under maintenance therapy with deflazacort and without insulin or medication for blood sugar control.
Edema
;
Epilepsies, Myoclonic/complications/drug therapy
;
Female
;
Humans
;
Hyperglycemia/*chemically induced
;
Immunosuppression
;
Insulin/therapeutic use
;
Lupus Nephritis/*complications/drug therapy
;
Middle Aged
;
Prednisolone/administration & dosage/*adverse effects/therapeutic use
;
Purpura, Thrombocytopenic, Idiopathic/complications/*drug therapy
6.Clinical significance of Helicobacter pylori in pathogenesis of idiopathic thrombocytopenic purpura.
Rong KONG ; Hong-Chun QIU ; Peng-Fei WU ; Xue-Hua NIU ; Wen-Xiang SHEN ; Yong WANG
Journal of Experimental Hematology 2008;16(5):1222-1226
This study was purposed to investigate the infection incidence of Helicobacter pylori (HP) in patients with idiopathic thrombocytopenic purpura (ITP) and curative efficacy of glucocorticoids combined with anti-helicobacter. 100 ITP patients with positive HP were divided randomly into 3 groups: glucocorticoid group (treatment with glucocorticoids, n = 35), anti-HP treatment group (HP eradication, n = 30) and combined treatment group (glucocorticoid combined with HP eradication, n = 35). 100 healthy individuals were selected as control. The results showed that HP infection rate in ITP group was 70%, while HP infection rate in control group (persons received physical examination) was 56%, there was significant difference between two groups (p < 0.05). The HP of 31 cases in combined treatment group was eradicated that the platelet count in 23 out of 31 cases recovered to normal, and in 8 cases was higher than that before treatment, which mean count was (165 +/- 225) x 10(9)/L, this value had statistical significance as compared with that before treatment (p < 0.01). Total efficiency in this group reached to 89%, and relapse rate within 1 year was 8%. The HP infection of 2 cases in glucocorticoid group had been turned to negative naturally, and platelet count recovered to normal, while HP infection in remained 33 cases was still positive. The platelet count in 23 out of 33 cases of that group was not back to normal, but back to normal in 10 cases. The platelet mean count in that group was (78 +/- 26) x 10(9)/L with total efficiency rate of 68% and relapse rate within 1 year was 37%. In the anti-HP treatment group, HP infection in 25 cases was eradicated and platelet count in 9 out of 25 cases recovered to normal, that platelet count in 9 cases was higher than that before treatment, platelet mean count was (135 +/- 174) x 10(9)/L), there was significant difference (p < 0.01), as compared with value before treatment. Total efficiency rate in this group reached to 60%, and relapse rate within 1 year was 33%. It is concluded that the patients with ITP have higher HP infection incidence, and the eradication of HP is effective therapy for the ITP patients with HP infection, which can be used as initial treatment.
Adult
;
Anti-Bacterial Agents
;
therapeutic use
;
Case-Control Studies
;
Combined Modality Therapy
;
Female
;
Glucocorticoids
;
therapeutic use
;
Helicobacter Infections
;
complications
;
drug therapy
;
Helicobacter pylori
;
Humans
;
Male
;
Platelet Count
;
Purpura, Thrombocytopenic, Idiopathic
;
complications
;
drug therapy
;
microbiology
7.Peliosis hepatis presenting with massive hepatomegaly in a patient with idiopathic thrombocytopenic purpura.
Sun Bean KIM ; Do Kyung KIM ; Sun Jeong BYUN ; Ji Hye PARK ; Jin Young CHOI ; Young Nyun PARK ; Do Young KIM
Clinical and Molecular Hepatology 2015;21(4):387-392
Peliosis hepatis is a rare condition that can cause hepatic hemorrhage, rupture, and ultimately liver failure. Several authors have reported that peliosis hepatis develops in association with chronic wasting disease or prolonged use of anabolic steroids or oral contraceptives. In this report we describe a case in which discontinuation of steroid therapy improved the condition of a patient with peliosis hepatis. Our patient was a 64-year-old woman with a history of long-term steroid treatment for idiopathic thrombocytopenic purpura . Her symptoms included abdominal pain and weight loss; the only finding of a physical examination was hepatomegaly. We performed computed tomography (CT) and magnetic resonance imaging (MRI) of the liver and a liver biopsy. Based on these findings plus clinical observations, she was diagnosed with peliosis hepatis and her steroid treatment was terminated. The patient recovered completely 3 months after steroid discontinuation, and remained stable over the following 6 months.
Adrenal Cortex Hormones/therapeutic use
;
Female
;
Hepatomegaly/complications/*diagnosis/pathology
;
Humans
;
Liver/pathology
;
Magnetic Resonance Imaging
;
Middle Aged
;
Peliosis Hepatis/complications/*diagnosis/pathology
;
Purpura, Thrombocytopenic, Idiopathic/complications/*diagnosis/drug therapy
;
Tomography, X-Ray Computed
;
Treatment Outcome
8.Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction with Idiopathic Thrombocytopenic Purpura: A Case Report.
Jun Hyung KIM ; Keon Uk PARK ; Woo Jung CHUN ; Seong Ho KIM ; Deuk Young NAH
Journal of Korean Medical Science 2006;21(2):355-357
Acute myocardial infarction (AMI) is rare in patients with idiopathic thrombocytopenic purpura (ITP). We describe a case of an AMI during thrombocytopenia in a patient with chronic ITP. A 47-yr-old woman presented with anterior chest pain and a low platelet count (21,000/microliter) at admission. Urgent coronary angiography revealed total occlusion of proximal right coronary artery and primary percutaneous coronary intervention (PCI) was performed successfully. This case suggests that primary PCI may be a therapeutic option for an AMI in patients with ITP, even though the patient had severe thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic/*complications/drug therapy
;
Myocardial Infarction/*complications/*therapy
;
Middle Aged
;
Immunoglobulins, Intravenous/administration & dosage/adverse effects
;
Humans
;
Heparin/administration & dosage/adverse effects
;
Female
;
Anticoagulants/administration & dosage/adverse effects
;
*Angioplasty, Transluminal, Percutaneous Coronary
9.Clinical significance of Helicobacter pylori in children with idiopathic thrombocytopenic purpura.
Ying TANG ; Shu-Chun WANG ; Lu-Juan WANG ; Yong LIU ; Hai-Ying WANG ; Zhan-Ju WANG
Journal of Experimental Hematology 2013;21(2):419-421
This study was aimed to investigate the clinic significance of helicobacter pylori (HP) in children with idiopathic thrombocytopenic purpura (ITP). The infection of HP in 92 ITP children was determined by (13) C-Urea Breath Test, the same test was also performed on 66 healthy children. The 68 children infected with HP were randomly divided into 2 groups: single drug group treated only with corticosteroid and; combined drug group treated with corticosteroid and anti-helicobacter pylori treatment. The results showed that 68 patients infected with HP were found in 92 ITP children (74.7%), 26 patients infected with HP were observed in 66 healthy children (39.4%), which was lower than that in ITP children (74.7%, P < 0.05). After anti-helicobacter pylori therapy, the total effective rate and cure rate of ITP patients increased respectively from 73.5% to 94.1%, and the total recurrence rate (17.0%) was much lower than single drug group (47.1%, P < 0.05). Otherwise, after therapy the platelet count in both two groups increased continuously, and at the same time point, the platelet count in anti-helicobacter pylori group was higher than that in the single drug group (P < 0.05). It is concluded that the ITP children have a higher infection rate of HP, which may be involved in the pathogenesis of ITP. Anti-helicobacter pylori therapy would help to improve the therapeutic efficacy and reduce the recurrence of ITP children.
Adrenal Cortex Hormones
;
therapeutic use
;
Breath Tests
;
Case-Control Studies
;
Child
;
Female
;
Helicobacter Infections
;
complications
;
drug therapy
;
Helicobacter pylori
;
Humans
;
Male
;
Platelet Count
;
Purpura, Thrombocytopenic, Idiopathic
;
complications
;
microbiology
;
Treatment Outcome
10.Outcome of Immunosuppressive Therapy with Helicobacter pylori Eradication Therapy in Patients with Chronic Idiopathic Thrombocytopenic Purpura.
Moo Kon SONG ; Joo Seop CHUNG ; Ho Jin SHIN ; Young Jin CHOI ; Goon Jae CHO
Journal of Korean Medical Science 2008;23(3):445-451
We initiated this study to investigate whether combining Helicobacter pylori eradication with immunosuppressive therapy provides an additional benefit to patients with idiopathic thrombocytopenic purpura (ITP) that has relapsed or has not responded to steroid and/or danazol therapy in patients who have H. pylori infection. Thirty- four patients with chronic ITP that had relapsed or failed to steroid and/or danazol therapy were assessed for H. pylori infection. Of the 21 confirmed cases, 12 patients were given H. pylori eradication therapy alone (EA), while 9 patients received eradication therapy combined with immunosuppressive therapy (EI). The response rate was not significantly different between patients in the EA and those in the EI group (41.7% in the EA group vs. 66.7% in the EI group, p=0.345). The median platelet count at 6 months after therapy was higher in the EI group patients (75X10(9)/L in the EI group patients vs. 18x109/L in the EA group patients, p=0.028). The median response duration was also longer in the EI group patients (9 months in the EI group patients vs. 3 months in the EA group patients, p=0.049). These results show that a significant benefit is gained by the use of H. pylori eradication combined with immunosuppressive therapy over the use of eradication therapy alone for patients with chronic ITP.
Adult
;
Aged
;
Anti-Bacterial Agents/*administration & dosage
;
Chronic Disease
;
Danazol/administration & dosage
;
Drug Therapy, Combination
;
Estrogen Antagonists/administration & dosage
;
Female
;
Helicobacter Infections/complications/*drug therapy
;
*Helicobacter pylori
;
Humans
;
Immunosuppressive Agents/*administration & dosage
;
Male
;
Middle Aged
;
Purpura, Thrombocytopenic, Idiopathic/complications/*drug therapy
;
Steroids/administration & dosage
;
Treatment Outcome